Market Research Case Study

CAR-T Cell Therapy: What 50 US and European Specialists Say About Efficacy, Safety and Access

An HCP perception study assessing awareness, clinical experience, perceptions of efficacy, safety concerns, treatment accessibility and future adoption potential of CAR-T cell therapy in oncology.

HCP Perception Study50 RespondentsUnited States & Europe
50HCPs
United States 25 (50%)Europe 25 (50%)
Haemato-oncologists
36%
Haematologists
24%
Medical oncologists
16%
Cellular therapy specialists
16%
Paediatric oncologists
8%
European coverageUK, Germany, France, Italy and Spain (5 respondents per country).
76%HCP familiarityModerate/high familiarity
64%Clinical benefitPositive clinical benefit perception
88%Major safety concernCytokine release syndrome (CRS)
68%Adoption willingnessPotential willingness to recommend or adopt

Research overview

Research typeHCP perception study
Sample size50 HCPs
GeographyUnited States and Europe

Introduction

CAR-T cell therapy is now a central topic for haematology and oncology teams, but awareness does not automatically translate into clinical use. To understand where perception, experience and adoption intent diverge, SPER Market Research conducted an HCP perception study of CAR-T cell therapy among 50 specialists in the United States and Europe. This article sets out what they said about efficacy, safety, access and the future of the therapy.

What is an HCP perception study in CAR-T?

An HCP perception study is primary market research that measures healthcare professionals' awareness, clinical experience, attitudes and likely adoption of a therapy. This study assessed HCP awareness, clinical experience, perceptions of efficacy, safety concerns, treatment accessibility and future adoption potential of CAR-T cell therapy in oncology.

Study design: 50 HCPs, split evenly between the United States (25) and Europe (25). European respondents came from the UK, Germany, France, Italy and Spain, five per country. By specialty, respondents were haemato-oncologists (36%), haematologists (24%), medical oncologists (16%), cellular therapy specialists (16%) and paediatric oncologists (8%). Multiple-response percentages are calculated against N=50, so totals may exceed 100%. Findings are directional and should not be interpreted as statistically representative of the overall HCP population.

Haemato-oncologists
36%
Haematologists
24%
Medical oncologists
16%
Cellular therapy specialists
16%
Paediatric oncologists
8%

Key findings at a glance

Key parameterFinding
Moderate/high HCP familiarity76%
Positive clinical benefit perception64%
Leading indication: B-cell NHL84%
Key advantage: durable responses82%
Major safety concern: CRS88%
Access and infrastructure barriers76%
Clinical involvement72%
Potential adoption willingness68%

How familiar are HCPs with CAR-T?

Seventy-six per cent of respondents are moderately (40%) or very (36%) familiar with CAR-T, while 24% report limited awareness. This reflects strong awareness among specialist oncology and haematology professionals.

Very familiar
36%
Moderately familiar
40%
Limited awareness
24%

Familiarity, however, is not the same as clinical experience. Twenty-four per cent prescribe or administer CAR-T, 22% manage patients after treatment and 26% refer eligible patients; 18% assess potential eligibility and 10% have no direct involvement. Seventy-two per cent report some form of clinical, patient management or referral involvement, which highlights the importance of distinguishing awareness from actual clinical experience.

Prescribing or administering CAR-T
24%
Post-treatment patient management
22%
Referring eligible patients
26%
Assessing potential eligibility
18%
No direct involvement
10%

How do specialists rate CAR-T clinical benefit?

Sixty-four per cent express positive perceptions of CAR-T's clinical benefit compared with available treatments for eligible relapsed/refractory patients (26% strongly agree, 38% agree). Twenty-two per cent are neutral and 14% disagree (10%) or strongly disagree (4%). Response durability, treatment line and patient eligibility remain important considerations.

Strongly agree
26%
Agree
38%
Neutral
22%
Disagree
10%
Strongly disagree
4%

The principal perceived advantages are:

Potential for durable clinical responses
82%
Targeted cancer cell recognition
78%
Option for relapsed/refractory patients
76%
Potential for long-term remission
68%
Personalised treatment approach
66%
Potential reduction in repeated treatment cycles
52%

Durable responses and targeted tumour-cell recognition stand out, particularly for patients with limited treatment alternatives.

Which cancers offer the greatest CAR-T potential?

Haematological malignancies remain the leading opportunity: B-cell non-Hodgkin lymphoma (84%), acute lymphoblastic leukaemia (74%), multiple myeloma (72%), chronic lymphocytic leukaemia (54%) and mantle cell lymphoma (52%). Solid tumours were selected by 34% and represent an emerging area requiring further clinical and technological advances.

B-cell non-Hodgkin lymphoma
84%
Acute lymphoblastic leukaemia (ALL)
74%
Multiple myeloma
72%
Chronic lymphocytic leukaemia (CLL)
54%
Mantle cell lymphoma
52%
Solid tumours
34%

What are the main safety concerns with CAR-T?

Cytokine release syndrome (CRS, 88%) and ICANS (84%) are the leading concerns. They are followed by:

Cytokine release syndrome (CRS)
88%
ICANS
84%
Infections and immune suppression
76%
Prolonged cytopenias
72%
Long-term safety and secondary malignancies
66%
Relapse and antigen escape
64%
B-cell aplasia and hypogammaglobulinaemia
58%
Manufacturing and product consistency
54%
Treatment-related mortality
48%

Infection risk, prolonged cytopenias and long-term safety also influence treatment decisions.

Do cost, infrastructure and accessibility limit CAR-T adoption?

Yes, according to 76% of respondents (38% strongly agree, 38% agree); 16% are neutral and 8% disagree. In the US, insurance coverage and affordability are important considerations. In Europe, reimbursement, HTA decisions and uneven treatment centre availability influence access.

Strongly agree
38%
Agree
38%
Neutral
16%
Disagree
6%
Strongly disagree
2%

Will HCPs recommend or adopt CAR-T?

Sixty-eight per cent indicate willingness to recommend or adopt CAR-T for eligible patients: 32% would definitely and 36% would probably do so. Twenty per cent are undecided and 12% would probably (8%) or definitely (4%) not. Actual adoption remains dependent on eligibility, clinical outcomes, reimbursement and treatment infrastructure.

Definitely would
32%
Probably would
36%
Undecided
20%
Probably would not
8%
Definitely would not
4%

What will shape CAR-T over the next 5–10 years?

Respondents named the following as the developments with the greatest impact:

Expansion across indications and earlier treatment lines
32%
Improved safety and toxicity management
20%
Allogeneic/off-the-shelf CAR-T
16%
Expansion into solid tumours
14%
In-vivo CAR-T
10%
Improved manufacturing and accessibility
8%

Future development will extend beyond indication expansion, with allogeneic platforms, in-vivo CAR-T, improved safety and manufacturing innovation emerging as important opportunities.

Frequently asked questions

What do physicians think of CAR-T cell therapy?

In this 50-HCP survey, 64% expressed positive perceptions of its clinical benefit, 76% were moderately or highly familiar with it, and 68% indicated willingness to recommend or adopt it.

What are the biggest safety concerns with CAR-T?

Cytokine release syndrome (88%) and ICANS (84%) lead, followed by infections and immune suppression (76%) and prolonged cytopenias (72%).

Which cancers do HCPs see as the best CAR-T opportunities?

B-cell non-Hodgkin lymphoma (84%), acute lymphoblastic leukaemia (74%) and multiple myeloma (72%).

What limits CAR-T adoption?

76% identified access-related barriers. In the US, insurance coverage and affordability; in Europe, reimbursement, HTA decisions and uneven treatment centre availability.

What developments will shape CAR-T next?

Expansion across indications and earlier lines (32%), improved safety and toxicity management (20%), allogeneic/off-the-shelf CAR-T (16%), solid tumours (14%) and in-vivo CAR-T (10%).

Can a 50-respondent survey represent all HCPs?

No. Findings are directional and should not be interpreted as statistically representative of the overall HCP population.

Conclusion

Specialists are familiar with CAR-T and largely positive about its clinical benefit, with durable responses the leading advantage. CRS and ICANS remain the dominant concerns, and 76% see cost, infrastructure and accessibility as barriers. With 68% willing to recommend or adopt it, adoption will depend on eligibility, clinical outcomes, reimbursement and treatment infrastructure. To explore HCP perception research for your therapy area, see SPER's primary intelligence services and KOL Atlas.

SPER MARKET RESEARCH · PRIMARY INTELLIGENCE

Planning research in cell therapy?

Talk to SPER Market Research about HCP perception studies tailored to your indication and markets.

Contact SPER Market Research →

Thought Leadership

Trusted by Industry Leaders

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.

SPER-Astellas Pharma
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-IQVIA
SPER-Mitsubishi Logistics
SPER-PACCOR
SPER-Macmillan Education
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-SAPTCA
SPER-Straumann
SPER-Danaher
SPER-AandM
SPER-MENARINI Silicon Biosystems
SPER-IPSOS
SPER-Heineken
HIPPA Compliant
GDPR Certified
ISO 27001
Peer Reviewed
Get Started Today

Your Competitive Advantage in
Pharmaceutical & Medical Technology
Markets

Join industry leaders leveraging AI-powered intelligence to make confident, data-driven decisions that accelerate breakthrough treatments and technologies to market.

No Credit Card Required
15-Minute Demo
Expert Guidance